812 related articles for article (PubMed ID: 15386308)
1. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
[TBL] [Abstract][Full Text] [Related]
2. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
3. Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behavior.
Tornóczky T; Kálmán E; Kajtár PG; Nyári T; Pearson AD; Tweddle DA; Board J; Shimada H
Cancer; 2004 Jan; 100(2):390-7. PubMed ID: 14716776
[TBL] [Abstract][Full Text] [Related]
4. Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular.
Umehara S; Nakagawa A; Matthay KK; Lukens JN; Seeger RC; Stram DO; Gerbing RB; Shimada H
Cancer; 2000 Sep; 89(5):1150-61. PubMed ID: 10964346
[TBL] [Abstract][Full Text] [Related]
5. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
6. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
7. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
8. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors.
Maitra A; Yashima K; Rathi A; Timmons CF; Rogers BB; Shay JW; Gazdar AF
Cancer; 1999 Feb; 85(3):741-9. PubMed ID: 10091748
[TBL] [Abstract][Full Text] [Related]
9. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol.
Navarro S; Amann G; Beiske K; Cullinane CJ; d'Amore ES; Gambini C; Mosseri V; De Bernardi B; Michon J; Peuchmaur M;
J Clin Oncol; 2006 Feb; 24(4):695-9. PubMed ID: 16446343
[TBL] [Abstract][Full Text] [Related]
11. The studies on the correlation for gene expression of tyrosine-kinase receptors and vascular endothelial growth factor in human neuroblastomas.
Zhang J; Zheng Y; Wang Y; Tong H
J Pediatr Hematol Oncol; 2010 Apr; 32(3):180-4. PubMed ID: 20186105
[TBL] [Abstract][Full Text] [Related]
12. The International Neuroblastoma Pathology Classification (the Shimada system).
Shimada H; Ambros IM; Dehner LP; Hata J; Joshi VV; Roald B; Stram DO; Gerbing RB; Lukens JN; Matthay KK; Castleberry RP
Cancer; 1999 Jul; 86(2):364-72. PubMed ID: 10421273
[TBL] [Abstract][Full Text] [Related]
13. Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas.
Tang XX; Evans AE; Zhao H; Cnaan A; Brodeur GM; Ikegaki N
Med Pediatr Oncol; 2001 Jan; 36(1):80-2. PubMed ID: 11464911
[TBL] [Abstract][Full Text] [Related]
14. [Pathology of peripheral neuroblastic tumors].
Wang L; He LJ; Shimada H
Zhonghua Bing Li Xue Za Zhi; 2012 Apr; 41(4):283-8. PubMed ID: 22800533
[No Abstract] [Full Text] [Related]
15. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
16. Surgical aspects of N-myc oncogene amplification of neuroblastoma.
Nakagawara A; Ikeda K; Yokoyama T; Tsuda T; Higashi K
Surgery; 1988 Jul; 104(1):34-40. PubMed ID: 3388178
[TBL] [Abstract][Full Text] [Related]
17. The calcium-sensing receptor and parathyroid hormone-related protein are expressed in differentiated, favorable neuroblastic tumors.
de Torres C; Beleta H; Díaz R; Toran N; Rodríguez E; Lavarino C; García I; Acosta S; Suñol M; Mora J
Cancer; 2009 Jun; 115(12):2792-803. PubMed ID: 19350667
[TBL] [Abstract][Full Text] [Related]
18. High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.
Tabyaoui I; Tahiri-Jouti N; Serhier Z; El Maani K; Cherkaoui S; Al Zemmouri M; Othmani MB; Zamiati S
Diagn Mol Pathol; 2013 Jun; 22(2):112-8. PubMed ID: 23628823
[TBL] [Abstract][Full Text] [Related]
19. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular.
Peuchmaur M; d'Amore ES; Joshi VV; Hata J; Roald B; Dehner LP; Gerbing RB; Stram DO; Lukens JN; Matthay KK; Shimada H
Cancer; 2003 Nov; 98(10):2274-81. PubMed ID: 14601099
[TBL] [Abstract][Full Text] [Related]
20. High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas.
Tang XX; Evans AE; Zhao H; Cnaan A; London W; Cohn SL; Brodeur GM; Ikegaki N
Clin Cancer Res; 1999 Jun; 5(6):1491-6. PubMed ID: 10389937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]